

ASX/Media Release

11 February 2020

Botanix Board Update

Philadelphia PA and Sydney, Australia, 11 February 2020: Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) today announced updates to its Board composition, with Matt Callahan re-joining the Botanix Board as an Executive Director and Rob Towner stepping down from his role as Non-Executive Director.

Vince Ippolito, President and Executive Chairman, commented: “We are delighted to have Matt re-join the Board and look forward to working together as Botanix approaches multiple significant clinical development milestones this year.

On behalf of the Botanix Board, I would like to thank Rob for his invaluable contribution since the Company’s inception. His contribution is greatly appreciated by the Company and he leaves on excellent terms. We wish him success in his future ventures going forward.”

Mr Callahan’s return comes at a time as the Company continues to progress multiple clinical development programs including: preparing for the end of Phase 2 meeting with the FDA (BTX 1503 Phase 2 acne study), nearing the completion of the BTX 1204 Phase 2 atopic dermatitis study, recent commencement of the new Phase 1b rosacea study and its antimicrobial product (BTX 1801) expected to enter Phase 2 clinical study in the near term.

Mr Towner, who has been a director of the Company since Botanix listed on the ASX in July 2016 and led the transaction to acquire Botanix in his previous role as a director of Bone Medical Ltd, has tendered his resignation as a Non-Executive Director, effective 11 February 2020. Mr Towner is currently Managing Director of Triangle Energy (Global) Limited (ASX:TEG) and holds other directorships that now require more of his time. The Botanix Board would like to thank Mr Towner for his valuable contribution to the Company during his time as Non-Executive Director.

Rob Towner said: “Botanix has rapidly evolved since I came onboard in mid-2016. It has achieved an enormous amount in that time and look forward to the Botanix team continuing to drive and achieve key clinical milestones in the near future.”

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company's focus is the development of safe and effective topical treatments for serious skin diseases, leveraging the unique anti-inflammatory, immune modulating and antimicrobial properties of synthetic cannabidiol. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases.

The Company has announced data from its Phase 2 acne patient study and is preparing for the end of Phase 2 meeting with the FDA. A Phase 2 patient study in atopic dermatitis is now fully recruited with data planned for 1Q CY2020 and its new Phase 1b rosacea study recently received ethics approval. The Company has also successfully completed a mechanism of action study for synthetic cannabidiol in skin disease, with positive data announced in June 2019 and is developing a pipeline of product candidates that leverages the antimicrobial properties of cannabidiol, with first products planned to enter the clinic in 1Q CY2020.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Joel Seah

Vesparum Capital

P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.